New York doctors testing heated chemo for rare cancer

March 5, 2009 By Delthia Ricks

Long Island cancer doctors have borrowed a page from medicine's past to write a new chapter on how to address a rare malignancy by infusing heated chemotherapy directly into the abdomen using a heart-lung machine.

The treatment is being tested at Stony Brook University Medical Center as a therapy for cancer of the appendix, a malignancy so rare it is known as an orphan cancer. The American Cancer Society has no statistics on its prevalence.

Dr. Colette Pameijer, a Stony Brook cancer surgeon and researcher, is treating appendiceal cancer with heated chemotherapy in what she interchangeably calls a "chemo bath" or, more technically, intraperitoneal hyperthermic chemoperfusion.

By warming the cancer drug, mitomycin, to about 107 degrees, it becomes a heated anti-cancer weapon when pumped through a catheter directly into the abdomen after surgery. The chemo bath is performed only once.

"We believe that in addition to the chemotherapy, the heat is directly toxic to the tumor cells," Pameijer said. She added the concept of a chemo bath for cancer of the appendix was first broached about 20 years ago by Dr. Paul Sugarbaker, a Washington cancer specialist and theorist who had researched new ways to approach appendiceal cancer, which can be resistant to chemotherapy.

He found when chemo is heated, its warmth zeros in on a key vulnerability of cancer cells -- they can't stand heat. Weakening the cancer with heat helps make the drug dramatically more effective.

Yet when Sugarbaker first advanced the notion of heat-treating cancer, he was met with a torrent of criticism from the medical establishment.

Pameijer said the therapy is not approved by the U.S. Food and Drug Administration, but she hopes to advance her work in the next two years to a formal nationwide clinical trial. "Not many people have it (appendiceal cancer) so it is difficult to do clinical trials," she said.

"With appendiceal cancer there isn't much funding so, yes, you do have to be a maverick," she said of taking bold steps in treatment strategies.

Cancer of the appendix, however, is not the only one short on research funding, experts say. Pancreatic cancer is another orphan malignancy for which there is little research funding, explained Kerry Kaplan, executive director of the Lustgarten Foundation for Pancreatic Cancer Research in Bethpage, N.Y. She, too, said people with common cancers have more political power as a group and can place more pressure on legislators for funding.

Dorothy Goncalves of Staten Island learned about Pameijer's chemo bath technique through her son and nephew, who are physicians. "I knew I had to have this," she said, adding there were few other treatments.

She said she had the treatment in September and all tests since that time have shown her to be cancer-free. "I just had a PET scan and CT scan and I am clean, no cancer at all."


(c) 2009, Newsday.
Visit Newsday online at
Distributed by McClatchy-Tribune Information Services.

Explore further: UH Case Medical Center offers new therapy for gynecologic cancer patients

Related Stories

UH Case Medical Center offers new therapy for gynecologic cancer patients

January 20, 2012
Patients with gynecologic cancer have new hope in a novel technology now offered at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center. A team of cancer specialists, led by Robert DeBernardo, MD, is ...

Natural process activating brain's immune cells could point way to repairing damaged brain tissue

October 21, 2012
The brain's key "breeder" cells, it turns out, do more than that. They secrete substances that boost the numbers and strength of critical brain-based immune cells believed to play a vital role in brain health. This finding ...

Recommended for you

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Mar 05, 2009
Heat INCREASES mitosis rate. Sounds like the opposite of what to do!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.